Browse > Article

The Investigator Initiated Clinical Trial in Japan  

Ahn, Byung-Jin (Department of Medicine, Graduate School, Dongguk University)
Lim, Chi-Yeon (Department of Medicine, Graduate School, Dongguk University)
Nagata, Ryuji (Pharmaceutical Safety Policy Division, Korea Food and Drug Administration)
Choi, Min-Joung (Advanced Therapy Products Research Division, Korea Food and Drug Administration)
Kim, Hee-Jung (College of Nursing, Catholic University of Daegu)
Lee, Jong-Tae (Department of Clinical Pharmacology and Therapeutics, Seoul St. Mary's Hospital, The Catholic University of Korea)
Yim, Hyeon-Woo (Department of Preventive Medicine, College of Medicine, The Catholic University of Korea)
Kim, Seong-Muk (Department of Neurosurgery, Seoul St. Mary's Hospital, The Catholic University of Korea)
Jeun, Sin-Soo (Department of Neurosurgery, Seoul St. Mary's Hospital, The Catholic University of Korea)
Publication Information
Journal of Korean Society for Clinical Pharmacology and Therapeutics / v.18, no.2, 2010 , pp. 96-108 More about this Journal
Abstract
Non-commercial investigator-initiated clinical trials are different from commercial trials sponsored by company according to trial purpose. Irrespective of Korean government’s efforts there are no definite guidelines for investigator-initiated clinical trials using unapproved drugs such as gene materials except clinical research using cell products and market-approved drugs. In USA and EU, the clinical trial results from non-commercial process could be used for marketing approval, if it is proven that the clinical trial has been done according to ICH-GCP guideline. However, In Japan, "chiken (clinical trial)" and "clinical research" are separated. In the clinical research except stem cell and gene therapy, the scientific and ethical aspects of new technology or therapeutics are reviewed only by the institutional review board (IRB), not by the regulatory agency. In the case of "chiken", the applicant has to submit a clinical trial application to the Pharmaceuticals and Medical Devices Agency (PMDA). To reduce administrative burdens and encourage the investigator-initiated trials, investigator-initiated chiken process was developed in Japan. Therefore, to improve and promote the clinical trials initiated by investigator in Korea, it is time to focus on Japan's investigator-initiated chiken process.
Keywords
Investigator- initiated; Clinical trial; Clinical research; Chiken; Japan;
Citations & Related Records
연도 인용수 순위
  • Reference
1 후생성 의약안전국장[厚生勞動省醫藥安全局長] 통지. 세포.조직을 이용한 의료용구 또는 의약품의 품질 및 안전성의 확보에 대하여, 1999, http://www.nihs.go.jp/cgtp/cgtp/guidline/99073 001.pdf, [online] (last visited on 15 Nov 2010)
2 후생성 의약안전국장[厚生勞動省醫藥安全局長] 통지. 인간 또는 동물 유래 성분을 원료로서 제조되는 의약품 등의 품질 및 안전성의 확보에 대하여, 2000, http://www.nihs.go.jp/cgtp/cgtp/ cgtp/guidline/00122601.pdf,[online] (last visited on 15 Nov 2010).
3 후생성 의약안전국장[厚生勞動省醫藥安全局長] 통지. 인(자기) 유래 세포나 조직을 가공한 의약품 또는 의료기기의 품질 및 안전성의 확보에 대하여, 2008, http://www.nihs.go.jp/cgtp/cg tp/guidline/0208003-200912-b2.pdf,[online] (last visited on 15 Nov 2010).
4 후생노동성 의약식품국장[厚生勞動省醫藥食品 局長] 통지. 인(동종) 유래 세포나 조직을 가공 한의약품 또는 의료기기의 품질 및 안전성의 확보에 대하여, 2008, http://www.nihs.go.jp/cgt p/cgtp/guidline/0912006-2002I200912006.pdf, [online] (last visited on 15 Nov 2010).
5 후생노동성[厚生勞動省]. 생물유래 원료기준, 2009.
6 대학병원 의료정보 network[UMIN] 임상시험등록 시스템[UMIN-CTR], http://www.umin.ac.jp /ctr/index.htm,[online] (last visited on 15 Nov 2010).21. JAPIC 임상시험 정보[ JAPIC CTI], http://www.clinicaltrials.jp/user/cte_main_e.jsp, [online] (last visited on 15 Nov 2010).
7 JAPIC 임상시험 정보[JAPIC CTI], www.://w ww.clinicaltrials.jp/user/cte_main_e.jsp, [online] (last visited on 15 Nov 2010).
8 일본의사회 치험촉진센터[JMA CCT] 임상시험 정보 등록 시스템, http://dbcentre3..jmacct.med .or.jp/jmactr/Default_Eng.aspx,[online] (last visited on 15 Nov 2010).
9 국립보건의료과학원[國立保健醫料科學院], 임상 연구(시험) 정보검색, http://rctportal.niph.go.jp /[online] (last visited on 15 Nov 2010).
10 후생노동성 의약식품국 심사관리과장[厚生勞動 省醫藥食品局審査管理課長] 통지. 치험심사위원회에 관한 정보의 등록에 대하여, 2008, http:w ww.pmda.go.jp/operations/shonin/info/chikenka nren/file/irb.pdf, [online] (last visited on 15 N ov 2010).
11 후생노동성 의정국장[厚生勞動省醫政局長] 통지 고도의료에 관한 신청 등의 취급 및 실시상의 유의사항에 대하여, 2009.
12 후생노동성 보험국 의료과장.치과의료관리관[厚 生勞動省保險局醫療課長.齒科醫料管理官] 통지. 후생노동대신[후생노동성 장관]이 정하는 선진 의료와 시설기준 제정 등에 따른 실시상의 유의사항 및 선진의료에 관한 신고 등의 취급에 대하여, 2009.
13 식품의약품안전청, 의약품 임상시험계획 승인 지침, 2009.
14 International Conference on Harmonization of Technical Requirements for Registration of Ph armaceuticals for Human Use, 1996.
15 European Science Foundation, Investigator-dri ven clinical trials, www.esf.org/fileadmin/links /EMRC/FL_IDCT.pdf [online] (last visited on 15 Nov 2010).
16 일본의사회[日本醫師會 The Japan Medical Ass ociation]. Center for Clinical Trials (JMA CCT ), http://www.jmacct.med.or.jp/share/images/en lish.pdf, [online] (last visited on 15 Nov 2010).
17 후생노동성[厚生勞動省] . 임상연구에 관한 윤리지침, 2008.
18 문부과학성[文部科學省].후생노동성[厚生勞動省]. 역학연구에 관한 윤리지침, 2007.
19 문부과학성[文部科學省] . 후생노동성[厚生勞動省].경제산업성[經濟産業省]. 인 게놈[genome].유전자 해석 연구에 관한 윤리지침, 2005.
20 문부과학성[文部科學省].후생노동성[厚生勞動省]. 유전자치료 임상연구에 관한 지침, 2004, http:// www.nihs.go.jp/cgtp/cgtp/guidline/04122802.pdf, [online] (last visited on 15 Nov 2010).
21 후생노동성[厚生勞動省] . 인 줄기세포를 사용하는 임상연구에 관한 지침, 2006.
22 일본약사법[藥事法], 2006.
23 후생성 약무국장[厚生省藥務局長] 통지. 치험약 의 제조관리 및 품질관리 기준 및 치험약 제조 시설의 구조설비 기준(치험약 GMP)에 대하여, 2007.
24 후생성령. 의약품의 임상시험 실시의 기준에 관한 성령, 2009.
25 후생노동성 의약식품국장[厚生勞動省醫藥食品局長] 통지. 유전자치료용 의약품의 품질 및 안전성의 확보에 관한 지침에 대하여, 2004.
26 The World Medical Association. Declaration o f Helsinki (6th ed.). 2008.